TCRT— Alaunos Therapeutics, Inc.

MaterialsBiotechnology$49M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenue	$5K-50.0%	$10K+100.0%	$5K-99.8%	$2.9M
Research and development	$1.4M+276.5%	$362K-97.8%	$16.3M-34.9%	$25.0M
General and administrative	$2.9M-35.7%	$4.5M-63.5%	$12.2M-7.0%	$13.1M
Total operating expenses	$4.2M-12.3%	$4.8M-85.9%	$34.3M-9.9%	$38.0M
Loss from operations	-$4.2M+12.2%	-$4.8M+86.0%	-$34.3M+2.4%	-$35.1M
Change in fair value of warrant liability	-$31K	$0	—	—
Other income , net	$80K-39.8%	$133K-87.3%	$1.0M+98.1%	$529K
Other income (expense), net	$49K-63.2%	$133K+115.2%	-$873K+66.7%	-$2.6M
Net loss	-$4.2M+10.8%	-$4.7M+86.7%	-$35.1M+6.9%	-$37.7M
Earnings per share, Basic	-$2.20+24.7%	-$2.92+86.7%	-$21.97-741.8%	-$2.61
Earnings per share, Diluted	-$2.20+24.7%	-$2.92+86.7%	-$21.97-741.8%	-$2.61
Weighted average common shares outstanding, basic	1.95B+21.7%	1.60B+0.1%	1.60B-88.9%	14.48B
Weighted average common shares outstanding, diluted	1.95B+21.7%	1.60B+0.1%	1.60B-88.9%	14.48B

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.